Gut bacteria link to immunotherapy sparks interest

One of the world’s largest cancer centers will collaborate with microbiome biotech Seres Therapeutics to investigate the gut microbiota’s role in shaping a patient’s response to immunotherapies. The MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy signed the agreement with the Cambridge, Massachusetts–based biotech in November. Read more in Nature Biotechnology.